Longeveron (LGVN) Depreciation & Amortization (CF) (2023 - 2026)
Longeveron's (LGVN) quarterly Depreciation & Amortization (CF) came in at $252000.0 in Q1 2026, down 40.14% year-on-year from $421000.0 in Q1 2025, and down 9.35% quarter-over-quarter from $278000.0 in Q4 2025.
Longeveron (LGVN) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Longeveron's Depreciation & Amortization (CF) history runs 4 years deep, the most recent figure standing at $252000.0 for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 40.14% year-over-year to $252000.0 in Q1 2026; TTM through Mar 2026 was $1.1 million, a 6.21% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, up 27.97% from the prior year.
- Depreciation & Amortization (CF) declined to $252000.0 in Q1 2026 per LGVN's latest filing, from $278000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $421000.0 in Q1 2025 and bottomed at $229000.0 in Q2 2024.
- The 4-year median for Depreciation & Amortization (CF) is $242000.0 (2024), against an average of $260153.8.
- Across the five-year window, Depreciation & Amortization (CF) soared 67.06% in 2025 and tumbled 40.14% in 2026, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $236000.0 in 2023, then grew by 2.54% to $242000.0 in 2024, then increased by 14.88% to $278000.0 in 2025, then declined by 9.35% to $252000.0 in 2026.
- Per Business Quant, the three latest LGVN Depreciation & Amortization (CF) figures stand at $252000.0 (Q1 2026), $278000.0 (Q4 2025), and $264000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | 252,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 252,000.00 |
| Mar 31, 2026 | 252,000.00 |
| Dec 31, 2025 | 278,000.00 |
| Dec 31, 2025 | 278,000.00 |
| Sep 30, 2025 | 264,000.00 |
| Sep 30, 2025 | 264,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Mar 31, 2025 | 421,000.00 |
| Mar 31, 2025 | 421,000.00 |
| Dec 31, 2024 | 242,000.00 |
| Dec 31, 2024 | 242,000.00 |
| Sep 30, 2024 | 235,000.00 |
| Sep 30, 2024 | 235,000.00 |
| Jun 30, 2024 | 229,000.00 |
| Jun 30, 2024 | 229,000.00 |
| Mar 31, 2024 | 252,000.00 |
| Mar 31, 2024 | 252,000.00 |
| Dec 31, 2023 | 236,000.00 |
| Dec 31, 2023 | 236,000.00 |